Targeting Cancer’s Hidden Driver Gilead Sciences’ Cot Kinase Modulators

Gilead Sciences, Inc. – one of the world’s leading biopharmaceutical companies – has filed a patent covering modulators of Cot (cancer Osaka thyroid) kinase, a protein implicated in inflammation, immune dysregulation and cancer. The invention provides new chemical entities designed to modulate Cot activity, along with methods for their therapeutic use across oncology, inflammatory disease and immune conditions.

The Problem

The Cot kinase – also known as TPL2 (Tumour Progression Locus 2) or MAP3K8 – is a serine-threonine kinase that plays an important role in intracellular signalling pathways controlling inflammation and immune responses. When Cot is activated, it drives downstream signalling through the MEK-ERK pathway, leading to the production of pro-inflammatory cytokines including TNF-alpha and other mediators that promote both inflammation and tumour progression.

In certain cancers, Cot is overexpressed or constitutively activated, contributing to the aggressive growth, survival and metastatic behaviour of tumour cells. It has been identified as a potential driver in multiple cancer types, particularly in haematological malignancies and some solid tumours. At the same time, Cot’s role in regulating inflammatory cytokine production makes it a target of interest in inflammatory and autoimmune conditions, where excessive cytokine signalling underlies tissue damage and disease progression.

Despite the therapeutic rationale for targeting Cot, developing selective, drug-like inhibitors or modulators has proven challenging. Cot shares structural features with other kinases, making selectivity a significant design challenge. Without selective modulators, any therapeutic effect in one pathway would likely be accompanied by off-target effects in others, limiting clinical utility. There has been a persistent need for well-characterised, selective Cot modulators with appropriate pharmaceutical properties for therapeutic development.

What This Invention Does

Gilead Sciences’ invention covers a class of chemical modulators of Cot activity – compounds designed to interact with and regulate the kinase in a way that modifies its downstream signalling effects. The patent covers the compounds themselves (under the C07D 401/14 heterocyclic chemistry classification), as well as pharmaceutical compositions containing them and methods of using them in therapeutic contexts.

The therapeutic scope of the invention is broad, spanning anti-cancer applications (A61P 35/00), anti-inflammatory applications (A61P 29/00), immune modulation (A61P 37/00) and metabolic conditions (A61P 3/00). This multi-indication coverage reflects the central role that Cot signalling plays across multiple disease biology contexts, and suggests that Gilead has developed evidence for the utility of these modulators in more than one clinical area.

As is typical for Gilead’s medicinal chemistry programmes, the compounds described in the patent are likely to have been optimised for selectivity, potency and drug-like properties including appropriate solubility, metabolic stability and cell permeability – the combination of attributes required for a compound to progress from laboratory curiosity to clinical drug candidate.

Key Features

Cot (TPL2/MAP3K8) kinase modulation. The compounds specifically target the Cot kinase, a key regulator of inflammatory and tumour-promoting signalling, providing a mechanism-based approach to disrupting pathological Cot activity.

Multi-indication therapeutic coverage. The invention is directed at oncology, inflammation, immune modulation and metabolic disease, reflecting the breadth of conditions in which aberrant Cot signalling has been implicated.

Heterocyclic compound class. The compounds fall within the C07D 401/14 classification – bridged heteroaromatic ring systems – a chemical class commonly associated with kinase inhibitor drugs due to their ability to interact with kinase ATP-binding sites.

Pharmaceutical composition and methods of use. Beyond the compounds themselves, the patent covers formulations and therapeutic uses, providing multi-layered protection across the drug development pathway.

Deep development lineage. This application is a second-generation divisional (divisional of AU 2024202085, which was itself a divisional of AU 2020290461), tracing back to a US provisional application from June 2019 – indicating a compound series that has been in active development for nearly seven years.

Who Is Behind It?

Gilead Sciences, Inc. is a Foster City, California-based biopharmaceutical company renowned for its antiviral medicines including HIV, hepatitis B and hepatitis C treatments, and more recently for its oncology and inflammatory disease pipeline. The inventors – Eda Y. Canales, Manoj C. Desai, Eric Gorman, Jiayao Li, Roland D. Saito, James G. Taylor and Nathan E. Wright – represent a substantial interdisciplinary team spanning medicinal chemistry, pharmacology and drug discovery. The application is filed through FPA Patent Attorneys in Melbourne.

Why It Matters

Kinase inhibitors have transformed oncology over the past two decades. From imatinib in chronic myeloid leukaemia to the explosion of targeted therapies in lung, breast and other cancers, the ability to selectively block signalling pathways that drive tumour growth has produced some of the most important advances in cancer treatment. The Cot/TPL2 pathway represents a node in inflammation and oncogenic signalling that has attracted significant scientific interest, with accumulating evidence supporting its role in tumour progression and inflammatory disease.

Gilead’s depth of investment in this target – evidenced by a development programme spanning seven or more years and multiple divisional patent filings – suggests genuine commitment to the clinical potential of Cot modulation. If selective Cot modulators with good pharmaceutical properties can be developed and validated in clinical trials, they could offer a new therapeutic option for patients with cancers or inflammatory conditions that are driven by aberrant Cot signalling and for whom existing therapies are inadequate. As the understanding of kinase biology in cancer continues to deepen, Cot modulation represents a scientifically well-grounded addition to the therapeutic toolkit being developed by the world’s leading pharmaceutical companies.

---

AU 2026201593 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.